Does Precocious Puberty Treatment Affect Future Fertility?

Current long-term research has not shown that pausing puberty with medication (GnRH agonists) harms a girl’s future fertility. While no treatment can guarantee future fertility—as it depends on many factors like age, genetics, and overall health—studies comparing women treated for central precocious puberty (CPP) to those who were not are highly reassuring ^[1][2].

GnRH agonists work by temporarily turning down the brain-to-ovary hormone signals that drive puberty. They do not damage the ovaries or permanently deplete a girl’s eggs.

Ovarian Reserve and Return of Menstruation

Parents often worry that suppressing the reproductive system might “use up” eggs. Studies tracking anti-Müllerian hormone (AMH)—an indirect blood marker related to the ovarian reserve—show temporary changes that reverse after treatment. AMH levels may decrease during treatment, but research shows they typically return to normal levels (comparable to girls without CPP) shortly after treatment stops ^[3]. (It is important to note that AMH is an indirect marker, not a direct egg count, and routine testing is not usually needed for a child).

After stopping medication, pubertal development generally resumes. On average, girls experience their first period (menarche) 12 to 17 months after discontinuing treatment, though this timeline varies based on the child’s age and biology ^[4][5]. Over 80% of women in long-term follow-up studies report having regular menstrual cycles in adulthood ^[4][2]. If pubertal signs or periods do not return as expected, the care team can assess the situation.

What Studies Show About Later Pregnancy

Data on adult women treated with GnRH agonists as children are encouraging, though it is important to note that studies are largely observational and involve limited cohort sizes. In one major study (the PREFER study), among women who actively tried to conceive, over 84% became pregnant within one year ^[6]. While only a small fraction (1.7%) of women in this study reported fertility problems, these studies track limited numbers of patients ^[6]. Still, researchers have consistently found that women with a history of treated CPP can go on to have normal reproductive function and healthy children ^[2].

Because your daughter has genetic CPP, it is also important to discuss with your doctor whether her specific genetic variation independently affects her reproductive health, separate from the puberty medication.

Understanding Polycystic Ovary Syndrome (PCOS) Risk

Parents frequently ask if GnRH agonists increase the risk of Polycystic Ovary Syndrome (PCOS), a condition involving irregular periods and hormone imbalances. While girls with a history of precocious puberty may have a slightly elevated risk of PCOS, available studies have not shown a clear increased risk from the medication itself ^[7].

When researchers compare girls with CPP who received GnRH agonists to those who did not, they find no statistically significant difference in PCOS rates ^[8][9]. The elevated risk is more likely tied to the underlying biology of early puberty, genetics, or metabolic factors rather than the medication used to pause it ^[7].

It is also completely normal for a girl’s periods to be irregular for a few years after her first period. An isolated irregular period does not mean she has PCOS; clinicians look for persistent irregularity and signs of excess androgens before making a diagnosis.